Phase 2 Trial of XPro1595 in Patients With Inflammation Being Planned

Phase 2 Trial of XPro1595 in Patients With Inflammation Being Planned

304114

Phase 2 Trial of XPro1595 in Patients With Inflammation Being Planned

A partnership agreement will allow INmune Bio to continue using biomarker imaging technology by Imeka in future clinical trials evaluating XPro1595, the company’s investigational therapy for Alzheimer’s disease. INmune Bio is planning to initiate a Phase 2 study of XPro1595 in Alzheimer’s patients this year, it stated in a press release. The agreement follows early evidence from its Phase 1b clinical trial (NCT03943264), which took place in Australia, that XPro1595’s use lowered white matter free water, a biomarker…

You must be logged in to read/download the full post.